LoadingLoadingLoadingNet selling: insiders sold $44.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
AQR
$208.7M
added
D.E. Shaw
$41.7M
added
Bank of America
$24.1M
added
No tracked top-trader positions in CORT as of Oct 24, 09:32 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Jul 29, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.04 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 23, 2026
EPS expected
$0.74 to $1.03
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 29, 2026 | $0.36 / -$0.04Alpha Vantage | +$0.40 beat | $256.1M No estimate | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | -$0.30 / -$0.14Alpha Vantage | -114.29% miss | $164.9M No estimate | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | $0.20 / $0.25Alpha Vantage | -21.26% miss | $202.1M No estimate | Unavailable |
| Sep 30, 2025 | Nov 4, 2025 | $0.16 / $0.14Alpha Vantage | +14.29% beat | $207.6M No estimate | Unavailable |
| Jun 30, 2025 | Jul 31, 2025 | $0.29 / $0.19Alpha Vantage | +52.63% beat | $194.4M No estimate | Unavailable |
| Mar 31, 2025 | May 5, 2025 | $0.17 / $0.14Alpha Vantage | +21.43% beat | $157.2M No estimate | Unavailable |
| Dec 31, 2024 | Feb 26, 2025 | Unavailable | - | $181.9M No estimate | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $0.41 / $0.29Alpha Vantage | +41.38% beat | $182.5M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $207.6M | $202.1M | $164.9M | $256.1M |
| Cost of what it sold | $4.6M | $2.5M | $2.9M | $4.1M |
| Gross profit | $203.0M | $199.6M | $162.0M | $252.1M |
| What it spent | ||||
| Research and development | $68.8M | $64.9M | $66.3M | $53.9M |
| Sales and admin | $124.0M | $130.2M | $145.4M | $156.9M |
| Total operating expenses | $192.8M | $195.1M | $211.6M | $210.8M |
| What was left | ||||
| Operating profit | $10.2M | $4.5M | -$49.6M | $41.3M |
| Profit before tax | $15.2M | $9.9M | -$44.7M | $45.9M |
| Tax | -$4.4M | -$14.4M | -$13.5M | -$2.9M |
| Net profit | $19.7M | $24.3M | -$31.2M | $42.1M |
| EBITDA | $15.7M | $10.4M | -$44.1M | $46.8M |
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
In a trial, 24% of patients with hard-to-control type 2 diabetes had excess cortisol.
BullishOct 20Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
BullishOct 20Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
BullishOct 20Corcept Therapeutics Incorporat (CORT) Stock forecasts
Leans bearishOct 19What Corcept Therapeutics Holders Saw Early
NeutralOct 18Corcept Therapeutics director Wilson sells $1.15 million in shares By Investing.com
NeutralOct 17What Corcept Therapeutics Holders Saw Early
NeutralOct 17Corcept Therapeutics Director James N. Wilson Sells 10,000 Shares on October 15 Under 10b5-1 Plan
NeutralOct 17
